Maxcyte (MXCT) Total Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has 7 years of Total Current Liabilities data on file, last reported at $10.2 million in Q1 2026.

• Quarterly Total Current Liabilities fell 19.8% year-over-year to $10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (down 19.8% YoY) and the FY2025 annual result came in at $14.3 million, down 9.56% from the prior year.
• Total Current Liabilities retreated to $10.2 million in Q1 2026 per MXCT's latest filing, from $14.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $18.1 million in Q2 2022 and bottomed at $10.2 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $15.5 million (2022), against an average of $15.0 million.
• The widest annual swing landed in 2022, when Total Current Liabilities surged 44.46%; it then dropped 27.08% in 2023.
• Tracing MXCT's Total Current Liabilities over 5 years: stood at $15.4 million in 2022, then grew by 15.74% to $17.9 million in 2023, then slipped by 11.65% to $15.8 million in 2024, then dropped by 9.56% to $14.3 million in 2025, then slipped by 28.42% to $10.2 million in 2026.
• Per Business Quant, the three latest MXCT Total Current Liabilities figures stand at $10.2 million (Q1 2026), $14.3 million (Q4 2025), and $16.1 million (Q3 2025).

Peer Comparison